active substance, excipient and primary container ...
Container integrity is discussed in ICH Q8, (adopted for human medicinal products only, nevertheless the same principles are also applicable to veterinary medicinal products and containers of sterile substances and containers). 2. Scope The guideline applies to chemical and biological medicinal products for human and veterinary use but is
Download active substance, excipient and primary container ...
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
Clean Rooms – Environmental Monitoring
web.njit.eduGood Manufacturing Practices – Medicinal Products for Human and Veterinary Use” ... critical stages of the manufacture of sterile products.” 1/26/2009. PhEn602 Pharmaceutical Facility Design Fall 2008. 33. Clean Rooms and Controlled Environments.
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ec.europa.euThis medicinal product is subject to additional monitoring. This will allow quick identification of ... (sterile concentrate). The vaccine is a white to off-white frozen dispersion (pH: 6.9 - 7.9). 4. CLINICAL PARTICULARS ... In order to improve the traceability of biological medicinal products, the name and the batch number .
Australian public assessment report for BNT162b2 (mRNA)
www.tga.gov.austerile frozen liquid, packaged in a multi dose clear glass 2 mL vial with a rubber stopper, stored in -60 to -90°C. The vials are packed in cartons containing 195 multi dose vials, and are intended for use over a short time window (calculated from its first use) due to …
ICH HARMONISED TRIPARTITE GUIDELINE
database.ich.orgIt applies to the manufacture of sterile APIs only up to the point immediately prior to the APIs being rendered sterile. The sterilization and aseptic processing of sterile APIs are not covered by this guidance, but should be performed in accordance with GMP guidelines for drug (medicinal) products as defined by local authorities.
Guide to Master Formulae Final - WHO
www.who.intCFR 21, Chapter I, Subchapter F: Biologics, Part 600 Biological Products: General; subpart B Establishment Standards, Sec 600.12 Records App 5-4) US FDA Guidelines for Batch Records for Sterile Products: Extract from: Guidance for Industry. Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice.
Glossary EN - updated legal references 08.2004
ec.europa.euGuidelines for the Manufacture of sterile medicinal products. CLEAN/CONTAINED AREA An area constructed and operated in such a manner that will achieve the aims of both a clean area and a contained area at the same time. CONTAINMENT The action of confining a biological agent or other entity within a defined space.
Quality Assurance of Aseptic Preparation Services: Standards
www.rpharms.comLicensed sterile medicinal products are used as ingredients or the ingredients are manufactured sterile in licensed facilities Products will be allocated a shelf life of no more than one week. The shelf life should be supported by stability data All activities should be in accordance with defined NHS guidelines.
NfG on Maximum shelf-life for sterile products for human use
www.ema.europa.eucommittee for proprietary medicinal products (cpmp) note for guidance on maximum shelf-life for sterile products for human use after first opening or following reconstitution discussion in the quality working party (qwp) june 1995 october 1995 february 1996 transmission to …